{"disease":{"id":"familial-hyperlipoproteinemia-type-1","name":"familial hyperlipoproteinemia type 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02658175","title":"The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT03360747","title":"Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Akcea Therapeutics","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}